Cargando…

Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration

BACKGROUND: Several intracellular signaling pathways that are deregulated during hepatocarcinogenesis might constitute potential targets for hepatocellular carcinoma (HCC) therapy. The aim of this study was to test the potential synergic antitumor effect of salirasib and sorafenib in a diethylnitros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciccarelli, Olga, Colson, Arthur, De Saeger, Christine, Reding, Raymond, Sempoux, Christine, Leclercq, Isabelle A, Stärkel, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200087/ https://www.ncbi.nlm.nih.gov/pubmed/30410370 http://dx.doi.org/10.2147/OTT.S176903

Ejemplares similares

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition
por: Charette, Nicolas, et al.
Publicado: (2010)

Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms
por: Charette, N, et al.
Publicado: (2013)

Combining Crocin and Sorafenib Improves Their Tumor-Inhibiting Effects in a Rat Model of Diethylnitrosamine-Induced Cirrhotic-Hepatocellular Carcinoma
por: Awad, Basma, et al.
Publicado: (2023)

An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors
por: Furuse, Junji, et al.
Publicado: (2018)

A Modified Protocol of Diethylnitrosamine Administration in Mice to Model Hepatocellular Carcinoma
por: Memon, Azra, et al.
Publicado: (2020)

Chronic Administration of Diethylnitrosamine and 2-Acetylaminofluorene Induces Hepatocellular Carcinoma in Wistar Rats
por: Sánchez-Meza, Jaime, et al.
Publicado: (2023)

β-Catenin Loss in Hepatocytes Promotes Hepatocellular Cancer after Diethylnitrosamine and Phenobarbital Administration to Mice
por: Awuah, Prince Kwaku, et al.
Publicado: (2012)

Gehua Jiecheng Decoction Inhibits Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice by Improving Tumor Immunosuppression Microenvironment
por: Cheng, Changpei, et al.
Publicado: (2020)

Tumor Promoting Effects of Sulforaphane on Diethylnitrosamine-Induced Murine Hepatocarcinogenesis
por: Zheng, Jie, et al.
Publicado: (2022)

Overexpression of Hepatocyte Chemerin-156 Lowers Tumor Burden in a Murine Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma
por: Haberl, Elisabeth M., et al.
Publicado: (2019)

Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib
por: Faigenbaum, Raya, et al.
Publicado: (2013)

Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures
por: Li, Dongli, et al.
Publicado: (2020)

Effect of Route of Administration on the Carcinogenic Action of Diethylnitrosamine (N-Nitrosodiethylamine)
por: Herrold, Katherine McD.
Publicado: (1964)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
por: Huang, Song-Fong, et al.
Publicado: (2022)

Antitumor effects of cadmium against diethylnitrosamine-induced liver tumors in mice
por: Nie, Yu, et al.
Publicado: (2022)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Maotai Ameliorates Diethylnitrosamine-Initiated Hepatocellular Carcinoma Formation in Mice
por: Yi, Xu, et al.
Publicado: (2014)

Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton
por: Mashiach-Farkash, Efrat, et al.
Publicado: (2012)

Expression profile of Oct-4 lung cancer-specific marker prior and subsequent to a salirasib treatment regime
por: Ao, Xiang, et al.
Publicado: (2017)

Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid
por: Li, Zhuo-Yue, et al.
Publicado: (2020)

Pharmacokinetic Exposures Associated With Oral Administration of Sorafenib in Dogs With Spontaneous Tumors
por: Cawley, Jacob R., et al.
Publicado: (2022)

Sex Hormone Dependency of Diethylnitrosamine‐induced Liver Tumors in Mice and Chemoprevention by Leuprorelin
por: Nakatani, Tamaki, et al.
Publicado: (2001)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
por: Tian, Xinchen, et al.
Publicado: (2022)

Accumulation of cholesterol, triglycerides and ceramides in hepatocellular carcinomas of diethylnitrosamine injected mice
por: Haberl, Elisabeth M., et al.
Publicado: (2021)

Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development
por: Delire, Bénédicte, et al.
Publicado: (2015)

Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat
por: Kumamoto, Ryo, et al.
Publicado: (2013)

Sorafenib Metabolism Is Significantly Altered in the Liver Tumor Tissue of Hepatocellular Carcinoma Patient
por: Ye, Ling, et al.
Publicado: (2014)

High-saturate-fat diet delays initiation of diethylnitrosamine-induced hepatocellular carcinoma
por: Duan, Xiao-Yan, et al.
Publicado: (2014)

Potential of siRNA-Bearing Subtilosomes in the Treatment of Diethylnitrosamine-Induced Hepatocellular Carcinoma
por: Jamal, Fauzia, et al.
Publicado: (2023)

Liver Protective Effects of Renin-Angiotensin System Inhibition Have No Survival Benefits in Hepatocellular Carcinoma Induced By Repetitive Administration of Diethylnitrosamine in Mice
por: Saber, Sameh, et al.
Publicado: (2018)

Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer
por: Wang, Jun, et al.
Publicado: (2021)

Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma
por: Nojiri, Shunsuke, et al.
Publicado: (2012)

The role of sorafenib in downsizing hepatocellular carcinoma prior to liver transplantation and in treating tumor recurrence
por: Sinakos, Emmanouil, et al.
Publicado: (2011)

Practical Effect of Sorafenib Monotherapy on Advanced Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis
por: Jeong, Soung Won, et al.
Publicado: (2013)

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma
por: Sakurai, Toshiharu, et al.
Publicado: (2017)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
por: Kusakabe, Yuko, et al.
Publicado: (2021)

Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
por: Davidi, Shiri, et al.
Publicado: (2022)

The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma
por: Chen, Siqi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ff7md0l8hnbll3soce11o8v1i4